Aktienanalyse zu IM Cannabis Corp (IMCC)IMCCIM Cannabis Corp

IM Cannabis Corp. is an international cannabis company that provides cannabis products to medical patients in Israel and Germany. The Company's ecosystem operates in Israel through its subsidiaries, which import and distribute cannabis to medical patients, leveraging years of proprietary data and patient insights. The Company also operates medical cannabis retail pharmacies, online platforms, distribution centers, and logistical hubs in Israel that enable the safe delivery and quality control of its products throughout the entire value chain. In Germany, the Company’s ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients. The Company's brands include The Craft Collection, The Top-Shelf Collection, The Signature Collection, The Full Spectrum Extracts, Roma, The WAGNERS, BLKMKT, LOT420, The PICO collection, and Flower. It operates in the Consumer Non-Cyclicals sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

IM Cannabis Corp. is not a good buy right now due to its significant financial struggles and negative market sentiment. The stock has dropped 96.89% year-to-date, and the current RSI is at 27.00, indicating it is oversold but still under pressure. Additionally, the company reported a net income loss of CAD 4.36 million in Q2 2026, which raises concerns about its profitability and sustainability.